Evidence map›Paper›PMID 39446149›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Facile fabrication of redox nanoparticles loaded with exosomal-miRNAs and resveratrol as glycation inhibitor in alleviating the progression and development of diabetic cataract.

Xia Chen, Qian Xi, Fei Sun, Lin Zou, Yingxuan Li

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Nanotechnology-Based Treatment for Ophthalmic Diseases.International journal of nanomedicine · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xia Chen *Department of Endocrinology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China. WD071057@usst.edu.cn.
Qian Xi *Department of Endocrinology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China.
Fei SunDepartment of Endocrinology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China.
Lin ZouDepartment of Endocrinology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China.
Yingxuan LiDepartment of Endocrinology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China.

Funding

the grants from the Key Specialty Construction Project of Pudong Health Bureau of Shanghai PWZzk2022-05the Special Clinical Research Project of Shanghai Health Commission 202040315
6 · The paper itself

Abstract

Diabetic cataract (DC) represents a highly prevalent ocular manifestation resulting from diabetes often culminating in vision impairment among individuals with diabetes. Regrettably, the armamentarium of pharmaceutical interventions capable of both delaying and thwarting the onset of DC remains conspicuously sparse. Based on contemporary investigations, the pathogenesis of DC is prominently influenced by oxidative harm to the crystalline lens and the nonenzymatic glycosylation of lens proteins. Consequently, we have developed self-regenerating cerium oxide nanoparticles (CeO

Indexed as

AntioxidantsCataractDiabetes ComplicationsMicroRNAsNanoparticlesResveratrolApoptosisCell LineCeriumDisease ProgressionExosomesGlycation End Products, AdvancedGlycosylationHumansLens, CrystallineOxidation-ReductionAntioxidantsceric oxideCeriumGlycation End Products, AdvancedMicroRNAsReactive Oxygen SpeciesResveratrolAntioxidantCeO2 NPsDiabetic cataractExosomal-miRNAGlycation inhibitorRSV

Identifiers

PMID39446149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.